24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Clinical
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
16:00
Lightricks challenges AI giants with open-source text-to-video platform
19:28
Full list of Israeli high-tech funding rounds in 2024
19:24
TailorMed raises $40 million in equity and debt to help patients access critical medications
18:17
Why Israeli tech companies are moving to Miami
More stories
Buzz
Most popular
Daily
Weekly
1
Stars over Athens: The who’s who at Calcalist's first Israel-Greece conference
2
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
3
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Claroty veterans launch Twine with $12M in Seed funding from Dell and Wiz founders to deploy AI cyber workers
More news
Clinical
1 stories about Clinical
Teva Discontinues Development of Cluster Headache Drug
24.04.19
|
Tzally Greenberg
Under Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment
Please ensure Javascript is enabled for purposes of
website accessibility
